These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 32340551)

  • 61.
    Erdogan T
    J Biomol Struct Dyn; 2023 Apr; 41(6):2448-2465. PubMed ID: 35088655
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Computational studies on the design of NCI natural products as inhibitors to SARS-CoV-2 main protease.
    Durgam L; Guruprasad L
    J Biomol Struct Dyn; 2023 Jun; 41(9):3741-3751. PubMed ID: 35333147
    [TBL] [Abstract][Full Text] [Related]  

  • 63.
    Kumar B; Parasuraman P; Murthy TPK; Murahari M; Chandramohan V
    J Biomol Struct Dyn; 2022 Oct; 40(17):7796-7814. PubMed ID: 33759690
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Potential protease inhibitors and their combinations to block SARS-CoV-2.
    Abhinand CS; Nair AS; Krishnamurthy A; Oommen OV; Sudhakaran PR
    J Biomol Struct Dyn; 2022 Feb; 40(2):903-917. PubMed ID: 32924827
    [TBL] [Abstract][Full Text] [Related]  

  • 65. 25 (S)-Hydroxycholesterol acts as a possible dual enzymatic inhibitor of SARS-CoV-2 M
    Alzahrani FA; Alkarim SA; Hawsawi YM; Abdulaal WH; Albiheyri R; Kurdi B; Alguridi H; El-Magd MA
    J Biomol Struct Dyn; 2023 Jul; 41(10):4744-4755. PubMed ID: 35510619
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Screening of plant-based natural compounds as a potential COVID-19 main protease inhibitor: an
    Majumder R; Mandal M
    J Biomol Struct Dyn; 2022 Feb; 40(2):696-711. PubMed ID: 32897138
    [TBL] [Abstract][Full Text] [Related]  

  • 67. SARS-CoV-2 ORF8 Protein Induces Endoplasmic Reticulum Stress-like Responses and Facilitates Virus Replication by Triggering Calnexin: an Unbiased Study.
    Wang X; Wang W; Wang T; Wang J; Jiang Y; Wang X; Qiu Z; Feng N; Sun W; Li C; Yang S; Xia X; He H; Gao Y
    J Virol; 2023 Mar; 97(3):e0001123. PubMed ID: 36877072
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Therapeutic potential of green tea catechin, (-)-epigallocatechin-3-
    Dinda B; Dinda S; Dinda M
    Phytomed Plus; 2023 Feb; 3(1):100402. PubMed ID: 36597465
    [TBL] [Abstract][Full Text] [Related]  

  • 69. SARS-CoV-2 Spike-Heat Shock Protein A5 (GRP78) Recognition may be Related to the Immersed Human Coronaviruses.
    Elfiky AA
    Front Pharmacol; 2020; 11():577467. PubMed ID: 33362542
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.
    Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP
    mBio; 2021 Mar; 12(2):. PubMed ID: 33785634
    [TBL] [Abstract][Full Text] [Related]  

  • 71. SARS-CoV-2 nonstructural protein 6 triggers endoplasmic reticulum stress-induced autophagy to degrade STING1.
    Jiao P; Fan W; Ma X; Lin R; Zhao Y; Li Y; Zhang H; Jia X; Bi Y; Feng X; Li M; Liu W; Zhang K; Sun L
    Autophagy; 2023 Dec; 19(12):3113-3131. PubMed ID: 37482689
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Rescuing the Host Immune System by Targeting the Immune Evasion Complex ORF8-IRF3 in SARS-CoV-2 Infection with Natural Products Using Molecular Modeling Approaches.
    Albutti A
    Int J Environ Res Public Health; 2021 Dec; 19(1):. PubMed ID: 35010372
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Multi-epitope vaccine against SARS-CoV-2 applying immunoinformatics and molecular dynamics simulation approaches.
    Jyotisha ; Singh S; Qureshi IA
    J Biomol Struct Dyn; 2022 Apr; 40(7):2917-2933. PubMed ID: 33164664
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Stilbene-based natural compounds as promising drug candidates against COVID-19.
    Wahedi HM; Ahmad S; Abbasi SW
    J Biomol Struct Dyn; 2021 Jun; 39(9):3225-3234. PubMed ID: 32345140
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Molecular screening of glycyrrhizin-based inhibitors against ACE2 host receptor of SARS-CoV-2.
    Ahmad S; Waheed Y; Abro A; Abbasi SW; Ismail S
    J Mol Model; 2021 Jun; 27(7):206. PubMed ID: 34169390
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Host-Cell Surface Binding Targets in SARS-CoV-2 for Drug Design.
    Maleksabet H; Rezaee E; Tabatabai SA
    Curr Pharm Des; 2022; 28(45):3583-3591. PubMed ID: 36420875
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Predictive modeling and therapeutic repurposing of natural compounds against the receptor-binding domain of SARS-CoV-2.
    Yadav MK; Ahmad S; Raza K; Kumar S; Eswaran M; Pasha Km M
    J Biomol Struct Dyn; 2023 Mar; 41(5):1527-1539. PubMed ID: 34974820
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The molecular dynamics of possible inhibitors for SARS-CoV-2.
    Irani AH; Steyn-Ross DA; Steyn-Ross ML; Voss L; Sleigh J
    J Biomol Struct Dyn; 2022; 40(20):10023-10032. PubMed ID: 34229582
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Targeting the N-terminal domain of the RNA-binding protein of the SARS-CoV-2 with high affinity natural compounds to abrogate the protein-RNA interaction: a molecular dynamics study.
    Khan S; Hussain Z; Safdar M; Khan A; Wei DQ
    J Biomol Struct Dyn; 2022 Sep; 40(14):6286-6294. PubMed ID: 33554747
    [TBL] [Abstract][Full Text] [Related]  

  • 80. An
    Stalin A; Lin D; Senthamarai Kannan B; Feng Y; Wang Y; Zhao W; Ignacimuthu S; Wei DQ; Chen Y
    J Biomol Struct Dyn; 2022 Oct; 40(16):7408-7423. PubMed ID: 33685364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.